Generally, the phenotype of subjects with MYBPC3 mutations is variable, and cardiac hypertrophy usually does not manifest until early adolescence with penetrance increasing with age and peaking at approximately 60 years of age [8–10]. The gene discussed is MYBPC3; the disease is cardiac hypertrophy.